Dr.Datsons Labs announced that the following changes in Directorship of the Company have taken place:1. The Change in designation of Rajendra Kamat, as a Non Executive Director of the Company with effect from 25 May 2015.2. Dinesh Surana, appointed as a Additional Director of the Company with effect from 25 May 2015.3. To accept the resignation of Shashikant Shinde as the Whole time Director of the Company w.e.f. 25 May 2015.4. To accept the resignation of Prabhat Kumar Goyal, as the Non Executive Director of the Company w.e.f. 25 May 2015.5. To accept the resignation of Minhaj Khan, as the Independent Director of the Company w.e.f. 20 May 2015.6. To accept the resignation of Mahesh Vaidya, as the Non Executive Chairman of the company w.e.f. 25 May 2015. Powered by Capital Market - Live News

Dr.Datsons Labs announced that Yogesh Patel, has resigned from the post of Company Secretary & Compliance Officer of the Company with effect from 12 May 2015.Powered by Capital Market - Live News

Dr.Datsons Labs announced that the Hon`ble Bombay High Court, while allowing certain application filed by the creditors of the Company in winding up petitions, vide its order dated 18 February 2015 (uploaded on website on 27 March 2015), appointed the official liquidator attached to the Bombay High Court as the provisional liquidator of Dr. Datsons Labs (the Company) and directed the provisional liquidator to forthwith take charge/possession of the Company`s assets, properties, stock in trade, books of account, bank account and all other assets of the Company.Pursuant to the aforesaid order, on 30 April 2015, the Official Liquidator took possession of the registered office of the Company along with moveable`s lying therein.Powered by Capital Market - Live News

Dr.Datsons Labs announced that Westminster Pharmaceuticals Inc. based out of USA has sent the Company a communication showing interest in Dr. Datsons Labs contract manufacturing Generic Medicines in Private Label for Westminster Pharmaceuticals Inc.Powered by Capital Market - Live News

Dr.Datsons Labs has forged a potential collaboration with Delhi based pharma company, Ochoa Laboratories to produce oncology drugs to cater to the European market worth Rs 120 crore. Dr.Datsons Labs has received the letter on 11 March 2015 for undertaking the contract manufacturing of the cancer drugs on a stipulated time line. Powered by Capital Market - Live News